AstraZeneca’s (AZN) positive interim results for its COVID-19 vaccine Monday was met with some confusion as health experts and Wall Street attempted to parse the company’s “up to 90%” and “average 70%” vaccine efficacy claims.
Score another pre-approval sale for coronavirus vaccine-maker Moderna (NASDAQ: MRNA). European Commission President Ursula von der Leyen has announced that the EC will ink a deal with the company on Wednesday. The contract will allow the European Union's member countries to purchase up to 160 million doses of Moderna's COVID-19 vaccine, mRNA-1273, once the vaccine is approved by EU regulators.
Interim data from late-stage studies on AstraZeneca (AZN) COVID-19 vaccine shows that the candidate was, on an average, about 70% effective in preventing COVID-19.